KRAS and metastatic colorectal cancer: A combination of the KRAS G12C inhibitor sotorasib with the anti-EGFR monoclonal antibody panitumumab is considered a recent advancement in the treatment of KRAS G12C-mutated metastatic colorectal cancer (mCRC).